Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,428,826
  • Shares Outstanding, K 642,063
  • Annual Sales, $ 3,121 M
  • Annual Income, $ 1,137 M
  • EBIT $ 857 M
  • EBITDA $ 1,032 M
  • 60-Month Beta 0.96
  • Price/Sales 6.22
  • Price/Cash Flow 19.94
  • Price/Book 3.38

Options Overview Details

View History
  • Implied Volatility 40.44% ( -10.76%)
  • Historical Volatility 32.12%
  • IV Percentile 12%
  • IV Rank 17.74%
  • IV High 93.64% on 02/12/25
  • IV Low 28.97% on 11/21/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 57
  • Volume Avg (30-Day) 119
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 3,362
  • Open Int (30-Day) 2,936

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.45
  • Number of Estimates 7
  • High Estimate 0.56
  • Low Estimate 0.36
  • Prior Year 0.57
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.08 +7.76%
on 11/05/25
33.65 -10.07%
on 10/16/25
-2.49 (-7.60%)
since 10/14/25
3-Month
23.14 +30.77%
on 08/15/25
33.65 -10.07%
on 10/16/25
+7.28 (+31.68%)
since 08/14/25
52-Week
17.24 +75.52%
on 04/09/25
33.65 -10.07%
on 10/16/25
+9.08 (+42.87%)
since 11/14/24

Most Recent Stories

More News
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader...

GMAB : 30.26 (+0.07%)
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Merus N.V....

GMAB : 30.26 (+0.07%)
MRUS : 95.95 (-0.14%)
Targeted Cell Therapies and Precision Degraders Drive $404B Cancer Market Expansion

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1],...

IOVA : 2.47 (+2.49%)
GMAB : 30.26 (+0.07%)
NRIX : 12.80 (+2.98%)
GTBP : 0.9206 (+26.14%)
SLS : 1.4300 (-2.05%)
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 demonstrated 50% confirmed objective response rate (ORR),...

GMAB : 30.26 (+0.07%)
Truist Financial Remains a Buy on Genmab (GMAB)

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab today. The company’s shares closed yesterday at $32.75.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

GMAB : 30.26 (+0.07%)
Deutsche Bank Remains a Buy on Genmab A/S (0MGB)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Genmab A/S today and set a price target of DKK2,000.00. The company’s shares closed last Friday at DKK2,079.33.Elevate Your Investing...

GMAB : 30.26 (+0.07%)
Genmab A/S (0MGB) Receives a Buy from UBS

UBS analyst Xian Deng maintained a Buy rating on Genmab A/S today and set a price target of DKK2,700.00. The company’s shares closed last Friday at DKK2,079.33.Elevate Your Investing Strategy: Take advantage...

GMAB : 30.26 (+0.07%)
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Genmab (GMAB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corcept Therapeutics (CORT – Research Report) and Genmab (GMAB – Research Report) with bullish sentiments.Elevate...

CORT : 75.54 (-0.28%)
GMAB : 30.26 (+0.07%)
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Merus N.V....

GMAB : 30.26 (+0.07%)
MRUS : 95.95 (-0.14%)
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD...

GMAB : 30.26 (+0.07%)
MRUS : 95.95 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 30.95
2nd Resistance Point 30.74
1st Resistance Point 30.50
Last Price 30.26
1st Support Level 30.05
2nd Support Level 29.84
3rd Support Level 29.60

See More

52-Week High 33.65
Last Price 30.26
Fibonacci 61.8% 27.38
Fibonacci 50% 25.44
Fibonacci 38.2% 23.51
52-Week Low 17.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar